Oasmia Pharma’s cancer drug received marketing approval in Kazakhstan

| By | Cancer Drugs, Kazakhstan

Oasmia Pharmaceutical, a Swedish developer of a new generation of drugs within human and veterinary oncology, announced that it has received marketing approval for Paclical in Kazakhstan.

Paclical is the first water-soluble cancer drug with paclitaxel to receive a market authorization. Paclical will be sold through Hetero Group and is planned to be launched during the first half of 2018.

Paclical, which has the name Apealea in Europe, is a novel formulation of paclitaxel based on Oasmia’s proprietary XR17 technology. It was approved for treatment of epithelial ovarian cancer. XR17 is non-toxic and forms water soluble nanoparticles with paclitaxel.

“The relationship established this year with Hetero Group grows further according to our plan with this approval,” says Julian Aleksov, Executive Chairman at Oasmia Pharmaceutical. “We are pleased to see this expansion into Kazakhstan, a country that we are confident will benefit from an additional and high-quality treatment now made available to physicians and patients. We look forward to Hetero’s work in generating sales in the region, and most importantly to Paclical making a difference in the lives of patients and their families.”

SOURCE: oasmia
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.